EZH2 and breast carcinoma: OGT-mediated O-GlcNAcylation of EZH2 attenuates EZH2 ubiquitination in breast cancer cell [36, 59]; PCAF-mediated EZH2-K348 acetylation inhibits CDK1 catalyzing pT345-EZH2 and pT487-EZH2 and increases EZH2 stability in lung cancer [37].